MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
PolyPid Ltd. Retained Earnings 2011-2026 | PYPD
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings PolyPid Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -302 M | -267 M | -238 M | -214 M | -175 M | -132 M | -93.3 M | -86.4 M | -92.3 M | -36.6 M | -25.2 M | - | -8.43 M | -4.55 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.55 M | -302 M | -129 M |
Quarterly Retained Earnings PolyPid Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -175 M | - | -151 M | - | -132 M | - | - | - | -93.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -93.3 M | -175 M | -138 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 4.12 | -0.36 % | $ 441 M |  USA |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arcturus Therapeutics Holdings
ARCT
|
-515 M | $ 8.32 | 3.67 % | $ 228 M |  Israel |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 23.65 | 0.08 % | $ 3.01 B | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.46 | 2.82 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-278 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioNTech SE
BNTX
|
-410 M | $ 91.44 | 0.29 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
BioXcel Therapeutics
BTAI
|
-720 M | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Cabaletta Bio
CABA
|
-517 M | $ 3.1 | 4.56 % | $ 311 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 3.17 | 1.44 % | $ 6.9 B | Israel |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Catalyst Biosciences
CBIO
|
-68.4 M | $ 19.48 | 0.39 % | $ 1.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Codexis
CDXS
|
-607 M | $ 1.95 | 6.87 % | $ 170 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-401 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-382 M | $ 3.01 | 0.67 % | $ 257 M | USA |
 |
Cerus Corporation
CERS
|
-1.08 B | $ 1.91 | 2.69 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
-588 M | $ 15.11 | 4.71 % | $ 910 M | USA |
 |
Coherus BioSciences
CHRS
|
-1.38 B | $ 1.72 | -0.87 % | $ 201 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-113 M | $ 0.46 | -13.02 % | $ 5.27 M | Israel |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-100 M | $ 2.25 | -0.44 % | $ 998 K | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
5.3 B | - | - | $ 96.9 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
474 M | $ 24.95 | 1.05 % | $ 3.05 B | USA |
 |
Celldex Therapeutics
CLDX
|
-1.81 B | $ 31.33 | 0.85 % | $ 2.08 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-555 M | $ 10.27 | 0.98 % | $ 137 M | USA |
 |
Cardiff Oncology
CRDF
|
-430 M | $ 1.6 | 1.27 % | $ 107 M | USA |
 |
Avenue Therapeutics
ATXI
|
-105 M | - | -52.27 % | $ 4.45 M | USA |